The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Methylated circulating tumor DNA (cfMeDIP) as a predictive biomarker of clinical outcome in pan-cancer patients (pts) treated with pembrolizumab (P).
 
Enrique Sanz Garcia
No Relationships to Disclose
 
Eric Y. Zhao
No Relationships to Disclose
 
Zhihui (Amy) Liu
No Relationships to Disclose
 
Kayla Marsh
No Relationships to Disclose
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Medison & Immunocore
Consulting or Advisory Role - Bristol-Myers Squibb; Medison & Immunocore; Merck; Novartis; Oncorus
Research Funding - Alkermes; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen; Treadwell Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Novartis; Novartis; Novocure; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Dax Torti
Employment - Ezra AI
Stock and Other Ownership Interests - Ezra AI
Research Funding - Ezra AI
Travel, Accommodations, Expenses - Ezra AI
 
Bernard Lam
No Relationships to Disclose
 
Trevor John Pugh
Honoraria - Merck
Consulting or Advisory Role - Axiom Healthcare Strategies; Chrysalis Biomedical Advisors
Research Funding - Roche
Patents, Royalties, Other Intellectual Property - Hybrid-capture sequencing for dete rmining immune cell clonality
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)